The phase 2 recruitment for Hansa Biopharma’s imlifidase research in Guillain-BarrĂ© syndrome has been completed, according to the company, a pioneer in enzyme technology for uncommon immunological disorders (GBS). The second half of 2023 is anticipated to see the release…